The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Amgen; Array BioPharma; Merck; Roche; Sanofi
Research Funding - Abbvie (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb; GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Roche (Inst); Sanofi (Inst)
Patient and tumor characteristics as determinants of overall survival (OS) in BRAF V600 mutant (mt) metastatic colorectal cancer (mCRC) treated with doublet or triplet targeted therapy.
 
Javier Ros Montañá
No Relationships to Disclose
 
Giulia Martini
No Relationships to Disclose
 
Iosune Baraibar
Consulting or Advisory Role - Sanofi
 
Guillermo Villacampa
Speakers' Bureau - MSD Oncology
 
Raquel Comas
No Relationships to Disclose
 
Davide Ciardiello
Travel, Accommodations, Expenses - Sanofi
 
Ariadna Garcia
No Relationships to Disclose
 
Xavier Hernandez Yague
No Relationships to Disclose
 
Bernardo Queralt
No Relationships to Disclose
 
Antonieta Salud Salvia
No Relationships to Disclose
 
Guillem Argiles
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Genentech/Roche; Roche; SERVIER
Travel, Accommodations, Expenses - Amgen; Bayer; Roche; SERVIER
 
Jose Luis Cuadra
Travel, Accommodations, Expenses - Amgen; Pfizer
 
Rodrigo A Toledo
Research Funding - Novartis
 
Irene Chicote
No Relationships to Disclose
 
Nuria Mulet
No Relationships to Disclose
 
Ana Vivancos
Consulting or Advisory Role - Bayer Health; Guardant Health; Novartis
 
Hector G. Palmer
Research Funding - Bayer; Blueprint Genetics; Cellestia Biotech; Merus; Novartis
 
Rodrigo Dienstmann
Consulting or Advisory Role - Roche
Speakers' Bureau - Amgen; Ipsen; MSD Oncology; Roche; Sanofi; SERVIER; Symphogen
Research Funding - Merck
 
Josep Tabernero
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; BeiGene; Biocartis; Boehringer Ingelheim; Chugai Pharma; Foundation Medicine; Genentech; Genmab; HalioDx; Halozyme; Imugene; Inflection Biosciences; Ipsen; Kura Oncology; Lilly; Menarini; Merck Serono; Merrimack; Merus; Molecular Partners; MSD; Novartis; Peptomyc; Pfizer; Pharmacyclics; ProteoDesign; Rafael Pharmaceuticals; Roche; Roche; Sanofi; Seagen; Seagen; Servier; Symphogen; Taiho Pharmaceutical; VCN Biosciences
 
Elena Elez
No Relationships to Disclose